Stijn Keereweer
Erasmus University Rotterdam
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Stijn Keereweer.
Molecular Imaging and Biology | 2011
Stijn Keereweer; Jeroen D. F. Kerrebijn; Pieter B. A. A. Van Driel; Bangwen Xie; Eric L. Kaijzel; Thomas J. A. Snoeks; Ivo Que; Merlijn Hutteman; Joost R. van der Vorst; J. Sven D. Mieog; Alexander L. Vahrmeijer; Cornelis J. H. van de Velde; Robert J. Baatenburg de Jong; Clemens W.G.M. Löwik
In cancer surgery, intra-operative assessment of the tumor-free margin, which is critical for the prognosis of the patient, relies on the visual appearance and palpation of the tumor. Optical imaging techniques provide real-time visualization of the tumor, warranting intra-operative image-guided surgery. Within this field, imaging in the near-infrared light spectrum offers two essential advantages: increased tissue penetration of light and an increased signal-to-background-ratio of contrast agents. In this article, we review the various techniques, contrast agents, and camera systems that are currently used for image-guided surgery. Furthermore, we provide an overview of the wide range of molecular contrast agents targeting specific hallmarks of cancer and we describe perspectives on its future use in cancer surgery.
Clinical Cancer Research | 2013
Stijn Keereweer; Pieter B. A. A. Van Driel; Thomas J. A. Snoeks; Jeroen D. F. Kerrebijn; Robert J. Baatenburg de Jong; Alexander L. Vahrmeijer; Henricus J. C. M. Sterenborg; Clemens W.G.M. Löwik
Optical image-guided cancer surgery is a promising technique to adequately determine tumor margins by tumor-specific targeting, potentially resulting in complete resection of tumor tissue with improved survival. However, identification of the photons coming from the fluorescent contrast agent is complicated by autofluorescence, optical tissue properties, and accurate fluorescent targeting agents and imaging systems. All these factors have an important influence on the image that is presented to the surgeon. Considering the clinical consequences at stake, it is a prerequisite to answer the questions that are essential for the surgeon. What is optical image-guided surgery and how can it improve patient care? What should the oncologic surgeon know about the fundamental principles of optical imaging to understand which conclusions can be drawn from the images? And how do the limitations influence clinical decision making? This article discusses these questions and provides a clear overview of the basic principles and practical applications. Although there are limitations to the intrinsic capacity of the technique, when practical and technical surgical possibilities are considered, optical imaging can be a very powerful intraoperative tool in guiding the future oncologic surgeon toward radical resection and optimal clinical results. Clin Cancer Res; 19(14); 3745–54. ©2013 AACR.
Oral Oncology | 2013
Joost R. van der Vorst; Boudewijn E. Schaafsma; F.P.R. Verbeek; Stijn Keereweer; Jeroen C. Jansen; Lilly Ann van der Velden; Antonius P. M. Langeveld; Merlijn Hutteman; Clemens W.G.M. Löwik; Cornelis J. H. van de Velde; John V. Frangioni; Alexander L. Vahrmeijer
OBJECTIVES Elective neck dissection is frequently performed during surgery in head and neck cancer patients. The sentinel lymph node (SLN) procedure can prevent the morbidity of a neck dissection and improve lymph node staging by fine pathology. Near-infrared (NIR) fluorescence imaging is a promising technique to identify the sentinel lymph node (SLN) intraoperatively. This feasibility study explored the use of indocyanine green adsorbed to human serum albumin (ICG:HSA) for SLN mapping in head and neck cancer patients. MATERIALS AND METHODS A total of 10 consecutive patients with oral cavity or oropharyngeal cancer and a clinical N0 neck were included. After exposure of the neck, 1.6 mL of ICG:HSA (500 μM) was injected at four quadrants around the tumor. During the neck dissection, levels I-IV were measured for fluorescence using the Mini-FLARE imaging system. RESULTS In all 10 patients, NIR fluorescence imaging enabled visualization of one or more SLNs. A total of 17 SLNs were identified. The mean contrast between the fluorescent signal of the lymph nodes and of the surrounding tissue was 8.7±6.4. In 3 patients, of which 1 was false-negative, lymph node metastases were found. After administration of ICG:HSA, the average number of fluorescent lymph nodes significantly increased over time (P<0.001). CONCLUSION This study demonstrated feasibility to detect draining lymph nodes in head and neck cancer patients using NIR fluorescence imaging. However, the fluorescent tracer quickly migrated beyond the SLN to higher tier nodes.
Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2012
Stijn Keereweer; H. J. C. M. Sterenborg; Jeroen D. F. Kerrebijn; P. B. A. A. van Driel; R. J. Baatenburg de Jong; Clemens W.G.M. Löwik
A key aspect for the postoperative prognosis of patients with head and neck cancer is complete tumor resection. In current practice, the intraoperative assessment of the tumor‐free margin is dependent on visual appearance and palpation of the tumor. Optical imaging has the potential of traversing the gap between radiology and surgery by providing real‐time visualization of the tumor, thereby allowing for image‐guided surgery. The use of the near‐infrared light spectrum offers 2 essential advantages: increased tissue penetration of light and an increased signal‐to‐background ratio of contrast agents.
The Journal of Nuclear Medicine | 2016
Eben L. Rosenthal; Jason M. Warram; Esther de Boer; James P. Basilion; Merrill A. Biel; Matthew Bogyo; Michael Bouvet; Brian E. Brigman; Yolonda L. Colson; Steven R. DeMeester; Geoffrey C. Gurtner; Takeaki Ishizawa; Paula Jacobs; Stijn Keereweer; Joseph C. Liao; Quyen T. Nguyen; James M. Olson; Keith D. Paulsen; Dwaine Rieves; Baran D. Sumer; Michael F. Tweedle; A.L. Vahrmeijer; Jamey P. Weichert; Brian C. Wilson; Kurt R. Zinn; Gooitzen M. van Dam
Navigation with fluorescence guidance has emerged in the last decade as a promising strategy to improve the efficacy of oncologic surgery. To achieve routine clinical use, the onus is on the surgical community to objectively assess the value of this technique. This assessment may facilitate both Food and Drug Administration approval of new optical imaging agents and reimbursement for the imaging procedures. It is critical to characterize fluorescence-guided procedural benefits over existing practices and to elucidate both the costs and the safety risks. This report is the result of a meeting of the International Society of Image Guided Surgery (www.isigs.org) on February 6, 2015, in Miami, Florida, and reflects a consensus of the participants’ opinions. Our objective was to critically evaluate the imaging platform technology and optical imaging agents and to make recommendations for successful clinical trial development of this highly promising approach in oncologic surgery.
Journal of Surgical Oncology | 2012
Stijn Keereweer; Isabel M. Mol; Jeroen D. F. Kerrebijn; Pieter B. A. A. Van Driel; Bangwen Xie; Robert J. Baatenburg de Jong; Alexander L. Vahrmeijer; Clemens W.G.M. Löwik
Near‐infrared (NIR) fluorescence optical imaging is a promising technique to assess the tumor margins during cancer surgery. This technique requires targeting by specific fluorescence agents to differentiate tumor from normal surrounding tissue. We assessed the feasibility of cancer detection using NIR fluorescence agents that target either αvβ3 integrins or the enhanced permeability and retention (EPR) effect in an orthotopic mouse model of oral cancer.
International Journal of Cancer | 2014
P. B. A. A. van Driel; J.R. van der Vorst; F.P.R. Verbeek; Sabrina Oliveira; Thomas J. A. Snoeks; Stijn Keereweer; B. Chan; Martin C. Boonstra; John V. Frangioni; P.M.P. van Bergen en Henegouwen; Alexander L. Vahrmeijer; Clemens W.G.M. Löwik
Intraoperative near‐infrared (NIR) fluorescence imaging is a technology with high potential to provide the surgeon with real‐time visualization of tumors during surgery. Our study explores the feasibility for clinical translation of an epidermal growth factor receptor (EGFR)‐targeting nanobody for intraoperative imaging and resection of orthotopic tongue tumors and cervical lymph node metastases. The anti‐EGFR nanobody 7D12 and the negative control nanobody R2 were conjugated to the NIR fluorophore IRDye800CW (7D12‐800CW and R2‐800CW). Orthotopic tongue tumors were induced in nude mice using the OSC‐19‐luc2‐cGFP cell line. Tumor‐bearing mice were injected with 25 µg 7D12‐800CW, R2–800CW or 11 µg 800CW. Subsequently, other mice were injected with 50 or 75 µg of 7D12‐800CW. The FLARE imaging system and the IVIS spectrum were used to identify, delineate and resect the primary tumor and cervical lymph node metastases. All tumors could be clearly identified using 7D12‐800CW. A significantly higher tumor‐to‐background ratio (TBR) was observed in mice injected with 7D12–800CW compared to mice injected with R2‐800CW and 800CW. The highest average TBR (2.00 ± 0.34 and 2.72 ± 0.17 for FLARE and IVIS spectrum, respectively) was observed 24 hr after administration of the EGFR‐specific nanobody. After injection of 75 µg 7D12‐800CW cervical lymph node metastases could be clearly detected. Orthotopic tongue tumors and cervical lymph node metastases in a mouse model were clearly identified intraoperatively using a recently developed fluorescent EGFR‐targeting nanobody. Translation of this approach to the clinic would potentially improve the rate of radical surgical resections.
Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2012
Stijn Keereweer; Jeroen D. F. Kerrebijn; Isabel M. Mol; J. Sven D. Mieog; Pieter B. A. A. Van Driel; Robert J. Baatenburg de Jong; Alexander L. Vahrmeijer; Clemens W.G.M. Löwik
In oral cancer surgery, intraoperative optical imaging could help the surgeon to determine adequate tumor‐free margins.
PLOS ONE | 2012
Bangwen Xie; Isabel M. Mol; Stijn Keereweer; Ermond van Beek; Ivo Que; Thomas J. A. Snoeks; Alan Chan; Eric L. Kaijzel; Clemens W.G.M. Löwik
Bioluminescence imaging (BLI) has shown its appeal as a sensitive technique for in vivo whole body optical imaging. However, the development of injectable tumor-specific near-infrared fluorescent (NIRF) probes makes fluorescence imaging (FLI) a promising alternative to BLI in situations where BLI cannot be used or is unwanted (e.g., spontaneous transgenic tumor models, or syngeneic mice to study immune effects). In this study, we addressed the questions whether it is possible to detect tumor progression using FLI with appropriate sensitivity and how FLI correlates with BLI measurements. In addition, we explored the possibility to simultaneously detect multiple tumor characteristics by dual-wavelength FLI (∼700 and ∼800 nm) in combination with spectral unmixing. Using a luciferase-expressing 4T1-luc2 mouse breast cancer model and combinations of activatable and targeting NIRF probes, we showed that the activatable NIRF probes (ProSense680 and MMPSense680) and the targeting NIRF probes (IRDye 800CW 2-DG and IRDye 800CW EGF) were either activated by or bound to 4T1-luc2 cells. In vivo, we implanted 4T1-luc2 cells orthotopically in nude mice and were able to follow tumor progression longitudinally both by BLI and dual-wavelength FLI. We were able to reveal different probe signals within the tumor, which co-localized with immuno-staining. Moreover, we observed a linear correlation between the internal BLI signals and the FLI signals obtained from the NIRF probes. Finally, we could detect pulmonary metastases both by BLI and FLI and confirmed their presence histologically. Taken together, these data suggest that dual-wavelength FLI is a feasible approach to simultaneously detect different features of one tumor and to follow tumor progression with appropriate specificity and sensitivity. This study may open up new perspectives for the detection of tumors and metastases in various experimental models and could also have clinical applications, such as image-guided surgery.
Acta Oto-laryngologica | 2012
Aniel Sewnaik; Stijn Keereweer; Abrahim Al-Mamgani; Robert J. Baatenburg de Jong; Marjan H. Wieringa; Cees A. Meeuwis; Jeroen D. F. Kerrebijn
Abstract Conclusions: Although organ preservation can be achieved with chemoradiation protocols for laryngeal or pharyngeal cancers, salvage surgery is accompanied by high complication rates. Objectives: To determine the rate of complications associated with salvage surgery after chemoradiation for laryngeal and pharyngeal cancers. Methods: A multicenter retrospective study was performed of 24 patients treated with total laryngectomy combined with total or partial pharyngectomy between 1995 and 2004 who had previously been treated with chemoradiation. The main outcome measures were early and late complication rates. Quality of life analysis was determined by two questionnaires. Results: The complication rate after salvage surgery was 92% in the direct postoperative period. The most frequent complication was pharyngocutaneous fistula formation. Narrowing of the esophagus and tracheostoma were the most common late sequelae. The quality of life, measured at least 2 years after salvage surgery, showed a social dysfunctioning.